Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vale SA — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vale SA trades at $13.09 (market cap $57.30B). The key difference: Vale SA is far larger — about 7.6× Spyre Therapeutics Inc. Common Stock's market cap, and Vale SA pays a 8.9% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vale SA for 110 Days on average.
| SYRE | VALE | |
|---|---|---|
Market Cap | $7.52B | $57.30B |
Volume | 1,441,031 | 25,010,417 |
Sector | Health | Basic Materials |
52-Week High | $108.92 | $17.82 |
52-Week Low | $22.18 | $11.10 |
Typical Hold Time | 0 Days | 110 Days |
Enterprise Value | $6.52B | $73.54B |
Dividend Yield | — | 8.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VALE trades at $13.21, down 2.29% today, with a bearish technical signal and three consecutive quarterly EPS misses. The stock shows mixed fundamentals with a P/E of 26.74 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from US steel expansion plans and rising operational costs.
Analyst consensus is cautious with 57% hold ratings and a $15.93 price target, suggesting 21% upside. Key risks include iron ore price volatility, Brazilian regulatory exposure, and margin compression from cost inflation. The base metals segment growth provides some diversification support amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
